Multimodal therapy and twenty years of valid management of a patient with chronic hepatitis B in a less developed Western Region in China---case report and review of the literature

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hepatitis B 18 infectiousdiseases
lamivudine 11 infectiousdiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
lamivudine 4310 Clinical diagnosis: (1) chronic active hepatitis; (2) early cirrhosis. Treatment regimen: 100 mg/day of lamivudine for 48 weeks, sequential use of INFa-1b (manufactured in China), 50 μg, im, three times a week,
lamivudine 4780 diffuse lesions of the liver, and splenomegaly. The patient began to orally receive 100 mg/day of lamivudine , and has continued this ever since. After 1 week of medication, the level of HBVDNA decreased below
lamivudine 8098 HBs(IU/L)HBeAg(COI)HBeAb(COI)HBcAb(COI)2012–1128.1< 20.10.0110.0092013–1111.11< 20.0760.0080.0052016–065.11< 20.030.0430.0032017–122.36< 20.1110.0840.010Table 3Cobas HBVDNA levels and Determination of lamivudine resistance sitesHBVDNA manufactured in ChinaCobas HBVDNA(IU/ml)Determination of lamivudine resistance< 103cps/ml–None< 103cps/ml–None2013–11< 500 IU/ml91YMDD
lamivudine 8189 Determination of lamivudine resistance sitesHBVDNA manufactured in ChinaCobas HBVDNA(IU/ml)Determination of lamivudine resistance< 103cps/ml–None< 103cps/ml–None2013–11< 500 IU/ml91YMDD tolerance2014–10< 500 IU/ml45Can’t
lamivudine 8645 (umol/L)AFP(ng/ml)CHE(IU/L)LSM(kPa)2013–11435046.2< 1058602014–10405348.1< 1062902016–06505451< 1063548.32017–12645340.3< 1065128.4Five-year medication: 100 mg of lamivudine , qd; 100 mg of silibinin, tid.Present diagnosis: hepatitis B and cirrhosis, compensatory stageState
lamivudine 10918 aggravate the condition” [[9]]. Hence, the patient received sequential therapy with 48 weeks of lamivudine and 24 weeks of interferon manufactured in China. Nine months after the end of the above-mentioned
lamivudine 11102 end of the above-mentioned treatments, the hepatitis became active again. At that time, except for lamivudine , there were no other nucleoside drugs available. Hence, the patient was asked to receive lamivudine
lamivudine 11202 lamivudine, there were no other nucleoside drugs available. Hence, the patient was asked to receive lamivudine treatment again, and has been taking lamivudine for 16 years. The HBVDNA test with a detection reagent
lamivudine 11250 available. Hence, the patient was asked to receive lamivudine treatment again, and has been taking lamivudine for 16 years. The HBVDNA test with a detection reagent manufactured in China was continuously negative.
lamivudine 11502 underwent Cobas HBVDNA test, and the result fluctuated within 45–91 IU/ml, the drug resistance of lamivudine was detected two times, and YMDD mutation was detected once. In the domestic and foreign guidelines
lamivudine 11642 YMDD mutation was detected once. In the domestic and foreign guidelines established in recent years, lamivudine was not recommended as the first line anti-hepatitis B virus drug [[5], [10], [11]]. However, in China,
Select Disease Character Offset Disease Term Instance
hepatitis B 112 Infectious DiseasesMultimodal therapy and twenty years of valid management of a patient with chronic hepatitis B in a less developed Western Region in China---case report and review of the literatureYue-Rong ZhangDe-Ming
hepatitis B 452 (pmc-release): 1/2019Publication date (collection): /2019AbstractBackgroundFor patients with chronic hepatitis B and cirrhosis in less developed western regions in China, due to constraints of local economic conditions,
hepatitis B 863 presentationThis study narrates the long-term treatment and careful follow-up of a patient with chronic hepatitis B and cirrhosis in a less developed western region in China, and analyzes the prognosis of the disease
hepatitis B 1082 countermeasures.ConclusionsThis would partly reflect the development of antiviral therapy for chronic hepatitis B and multidisciplinary comprehensive treatment for cirrhosis-related complications in remote region with
hepatitis B 1279 remote region with limited resources in the past 20 years.BackgroundThe widespread inoculation of hepatitis B vaccine has reduced the infection rate of hepatitis B virus from 9.75%, 20 years ago, to 7.18%, 10 years
hepatitis B 1333 20 years.BackgroundThe widespread inoculation of hepatitis B vaccine has reduced the infection rate of hepatitis B virus from 9.75%, 20 years ago, to 7.18%, 10 years ago in China [[1], [2]]. With the development
hepatitis B 1632 patients can achieve better therapeutic effect and prognosis [[3]]. However, for patients with chronic hepatitis B and cirrhosis in less developed western regions in China, due to constraints of local economic conditions,
hepatitis B 1914 improvement of the overall medical technology level, it has become possible to choose the precise anti- hepatitis B virus therapy and multidisciplinary treatment for cirrhosis-related complications, according to the
hepatitis B 2292 transplantation. Hence, it is a valuable clinical attempt. The diagnosis and treatment of a patient with hepatitis B and cirrhosis is reported, as follows.Case presentationThe patient is a male, who was born in October
hepatitis B 2527 patient is a resident of Lanzhou, Gansu Province, and is a worker. He denies any family history of hepatitis B .This study was conducted in accordance with the declaration of Helsinki and was conducted with approval
hepatitis B 2920 hospitalized due to fatigue and yellow staining of the skin and mucosa for 10 days. Serum markers of hepatitis B virus at admission: HBsAg (+), anti-HBe (+), and anti-HBc (+). Liver function: total bilirubin (TBIL),
hepatitis B 3244 Abdominal ultrasonography results: liver echo enhancement and mild splenomegaly. Clinical diagnosis: active hepatitis B . After liver-protecting treatment, the condition of patient improved, and the patient was discharged.In
hepatitis B 8705 (umol/L)AFP(ng/ml)CHE(IU/L)LSM(kPa)2013–11435046.2< 1058602014–10405348.1< 1062902016–06505451< 1063548.32017–12645340.3< 1065128.4Five-year medication: 100 mg of lamivudine, qd; 100 mg of silibinin, tid.Present diagnosis: hepatitis B and cirrhosis, compensatory stageState after EVL for exophageal varicesState after the operation for
hepatitis B 9045 characteristics: (1) The patient had an onset of the disease at youth, denied any family history of hepatitis B , and was a hepatitis B patient without mother-to-infant vertical transmission. (2) Since the primarily
hepatitis B 9068 The patient had an onset of the disease at youth, denied any family history of hepatitis B, and was a hepatitis B patient without mother-to-infant vertical transmission. (2) Since the primarily diagnosis in June 1996,
hepatitis B 10113 typical case of the long-term management of chronic diseases.The characteristics of antiviral therapy for hepatitis B : Twenty years ago, interferon was the only drug that could inhibit hepatitis B virus in China [[7]].
hepatitis B 10192 antiviral therapy for hepatitis B: Twenty years ago, interferon was the only drug that could inhibit hepatitis B virus in China [[7]]. However, the interferon manufactured in China had the characteristics of weak
hepatitis B 11696 foreign guidelines established in recent years, lamivudine was not recommended as the first line anti- hepatitis B virus drug [[5], [10], [11]]. However, in China, there were still some patients who have been treated

You must be authorized to submit a review.